Standard ADHD stimulant protocols treat dosage as a static daily variable. For menstruating women with ADHD, this model is fundamentally flawed. Over 40 days of self-tracked symptom data — including medication response, cognitive performance, hyperfocus episodes, emotional dysregulation, appetite, sleep, and executive function — I observed a clear and repeatable pattern: stimulant efficacy does not remain constant across the menstrual cycle. It fluctuates dramatically, and the fluctuation maps onto hormonal phases with striking precision. The proposed mechanism: Estrogen acts as a dopamine amplifier — it increases dopamine synthesis, limits reuptake via MAO inhibition, and sensitizes dopamine receptors in the prefrontal cortex and basal ganglia. Since ADHD stimulants work precisely by modulating dopaminergic pathways, high-estrogen phases (follicular, late follicular/ovulatory) create a synergistic environment where stimulants appear more effective. During the luteal and premenstrual phases, estrogen withdrawal produces the opposite effect: the same dose of medication feels insufficient, cognitive performance deteriorates, and emotional dysregulation escalates. What I documented in my own cycle:

Day 9 post-period onset: Stimulant felt notably more effective — rapid satiety, high task completion, no anxiety, gym + multiple productive tasks in a single day. Ovulatory/late follicular window: Sustained hyperfocus episodes of 8–12 hours, high creative output, low distractibility. Luteal phase: Fragmented hyperfocus — simultaneous impulses to work on tasks. High energy but low executive control over direction. Premenstrual (days −3 to 0): Complete executive collapse. Inability to experience joy, anhedonia, suicidal ideation, hypersensitivity to news, non-restorative sleep, inability to leave bed. Day 1 of period: Rapid mood recovery — energy, singing, engagement — before stimulant was even taken.

The falsifiable claim: If estrogen modulates dopaminergic tone in women with ADHD, then stimulant efficacy (measured by task completion rate, hyperfocus duration, executive function self-report, and emotional regulation) should peak in the late follicular phase and hit a minimum in the mid-to-late luteal phase — independently of dosage. A fixed daily dose therefore produces inconsistent therapeutic coverage across the cycle, representing a systematic treatment gap that disproportionately affects women. Implication: Cycle-aware dosing — adjusting stimulant dose upward in the luteal/premenstrual phase and potentially downward in the high-estrogen follicular phase (to avoid overstimulation) — could dramatically improve treatment outcomes and quality of life. This is not speculative: a 2023 pilot study in Frontiers in Psychiatry found that premenstrual dose adjustments significantly improved both cognitive and emotional ADHD symptoms in women with comorbid PMDD. Yet this approach remains clinically rare. What's missing: Longitudinal studies with daily hormone assays alongside standardized cognitive testing and stimulant plasma levels across full cycles. N=1 observational data like mine can only point the direction. But the direction is clear, and the research gap is inexcusable given how many women are currently undertreated by a one-size-fits-all dosing model designed without their biology in mind. I'm building a cycle-tracking app (Lilith) specifically designed to capture this data at scale from neurodivergent women. The hypothesis is simple: your medication doesn't change. Your hormones do. And nobody told you that.